Biopharma Modalities VC Funding Consolidates in Q1, But Annual Investment Surges Past $31 Billion
Venture capital activity in the biopharma modalities sector continued to consolidate in the first quarter of 2025, according to PitchBook’s latest Emerging Tech Research. Deal volume declined by more than 18% compared to the previous quarter, reflecting growing investor selectivity and ongoing macroeconomic pressures. Despite the dip in activity, total deal value remained stable, indicating […]
Continue Reading